Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Transcatheter Arterial Chemoembolization for Infiltrative Hepatocellular Carcinoma: Clinical Safety and Efficacy and Factors Influencing Patient Survival

  • Han, Kichang (Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Jin Hyoung (Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Yoon, Hee Mang (Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Eun-Joung (Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Gwon, Dong Il (Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Ko, Gi-Young (Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Yoon, Hyun-Ki (Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Ko, Heung Kyu (Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2013.10.17
  • Accepted : 2014.03.20
  • Published : 2014.07.01
⟨ Previous Next ⟩

Abstract

Objective: To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) in patients with infiltrative hepatocellular carcinoma (HCC) and to identify the prognostic factors associated with patient survival. Materials and Methods: Fifty two patients who underwent TACE for infiltrative HCC were evaluated between 2007 and 2010. The maximum diameter of the tumors ranged from 7 cm to 22 cm (median 15 cm). Of 46 infiltrative HCC patients with portal vein tumor thrombosis, 32 patients received adjuvant radiation therapy for portal vein tumor thrombosis after TACE. Results: The tumor response by European Association for the Study of the Liver criteria was partial in 18%, stable in 47%, and progressive in 35% of the patients. The median survival time was 5.7 months (Kaplan-Meier analysis). The survival rates were 48% at six months, 25% at one year, and 12% at two years. In the multivariable Cox regression analysis, Child-Pugh class (p = 0.02), adjuvant radiotherapy (p = 0.003) and tumor response after TACE (p = 0.004) were significant factors associated with patient survival. Major complications occurred in nine patients. The major complication rate was significantly higher in patients with Child-Pugh B than in patients with Child-Pugh A (p = 0.049, ${\chi}^2 $ test). Conclusion: Transcatheter arterial chemoembolization can be a safe treatment option in infiltrative HCC patients with Child Pugh class A. Child Pugh class A, radiotherapy for portal vein tumor thrombosis after TACE and tumor response are good prognostic factors for an increased survival after TACE in patients with infiltrative HCCs.

Keywords

References

  1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750 https://doi.org/10.1056/NEJM199903113401001
  2. Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. Jpn J Clin Oncol 2012;42:247-255 https://doi.org/10.1093/jjco/hys020
  3. Demirjian A, Peng P, Geschwind JF, Cosgrove D, Schutz J, Kamel IR, et al. Infiltrating hepatocellular carcinoma: seeing the tree through the forest. J Gastrointest Surg 2011;15:2089-2097 https://doi.org/10.1007/s11605-011-1614-7
  4. Kanematsu M, Semelka RC, Leonardou P, Mastropasqua M, Lee JK. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 2003;18:189-195 https://doi.org/10.1002/jmri.10336
  5. Kneuertz PJ, Demirjian A, Firoozmand A, Corona-Villalobos C, Bhagat N, Herman J, et al. Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes. Ann Surg Oncol 2012;19:2897-2907 https://doi.org/10.1245/s10434-012-2336-0
  6. Hu HT, Kim JH, Lee LS, Kim KA, Ko GY, Yoon HK, et al. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. J Vasc Interv Radiol 2011;22:917-923 https://doi.org/10.1016/j.jvir.2011.03.005
  7. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739 https://doi.org/10.1016/S0140-6736(02)08649-X
  8. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011;18:413-420 https://doi.org/10.1245/s10434-010-1321-8
  9. Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol 2013;13:60 https://doi.org/10.1186/1471-230X-13-60
  10. Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 1995;165:315-321 https://doi.org/10.2214/ajr.165.2.7618547
  11. Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 2009;24:806-814 https://doi.org/10.1111/j.1440-1746.2008.05728.x
  12. Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011;258:627-634 https://doi.org/10.1148/radiol.10101058
  13. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171 https://doi.org/10.1053/jhep.2002.33156
  14. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022 https://doi.org/10.1002/hep.24199
  15. Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002;87:13-15
  16. Yoon HM, Kim JH, Kim EJ, Gwon DI, Ko GY, Ko HK. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort. J Vasc Interv Radiol 2013;24:1639-1646 https://doi.org/10.1016/j.jvir.2013.06.017
  17. Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012;82:2004-2011 https://doi.org/10.1016/j.ijrobp.2011.03.019
  18. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236 https://doi.org/10.1002/hep.20933
  19. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009;250:466-473 https://doi.org/10.1148/radiol.2502072222
  20. Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009;20(7 Suppl):S425-S434 https://doi.org/10.1016/j.jvir.2009.04.021
  21. Trevisani F, Caraceni P, Bernardi M, DʹIntino PE, Arienti V, Amorati P, et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 1993;72:1557-1563 https://doi.org/10.1002/1097-0142(19930901)72:5<1557::AID-CNCR2820720512>3.0.CO;2-5
  22. Lopez RR Jr, Pan SH, Hoffman AL, Ramirez C, Rojter SE, Ramos H, et al. Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. Arch Surg 2002;137:653-657; discussion 657-658 https://doi.org/10.1001/archsurg.137.6.653
  23. Jang ES, Yoon JH, Chung JW, Cho EJ, Yu SJ, Lee JH, et al. Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. J Cancer Res Clin Oncol 2013;139:635-643 https://doi.org/10.1007/s00432-012-1364-2
  24. Yamada K, Izaki K, Sugimoto K, Mayahara H, Morita Y, Yoden E, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003;57:113-119 https://doi.org/10.1016/S0360-3016(03)00434-6
  25. Zeng ZC, Fan J, Tang ZY, Zhou J, Qin LX, Wang JH, et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2005;61:432-443 https://doi.org/10.1016/j.ijrobp.2004.05.025
  26. Ishikura S, Ogino T, Furuse J, Satake M, Baba S, Kawashima M, et al. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002;25:189-193 https://doi.org/10.1097/00000421-200204000-00019
  27. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-469 https://doi.org/10.1053/j.gastro.2006.05.021

Cited by

  1. Transarterial Chemoembolization and90Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease vol.205, pp.4, 2014, https://doi.org/10.2214/ajr.15.14802
  2. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system vol.21, pp.36, 2014, https://doi.org/10.3748/wjg.v21.i36.10327
  3. Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival? vol.2016, pp.None, 2016, https://doi.org/10.1155/2016/4692139
  4. Optimized Performance of FlightPlan during Chemoembolization for Hepatocellular Carcinoma: Importance of the Proportion of Segmented Tumor Area vol.17, pp.5, 2014, https://doi.org/10.3348/kjr.2016.17.5.771
  5. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review vol.22, pp.1, 2014, https://doi.org/10.3748/wjg.v22.i1.407
  6. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein vol.22, pp.13, 2014, https://doi.org/10.3748/wjg.v22.i13.3632
  7. Liver Abscess Formation Following Transarterial Chemoembolization : Clinical Features, Risk Factors, Bacteria Spectrum, and Percutaneous Catheter Drainage vol.95, pp.17, 2014, https://doi.org/10.1097/md.0000000000003503
  8. Infiltrative Hepatocellular Carcinoma : Assessment of Factors Associated With Outcomes in Patients Undergoing Hepatectomy vol.95, pp.19, 2014, https://doi.org/10.1097/md.0000000000003589
  9. N-Butyl-2-cyanoacrylate-based injectable and in situ-forming implants for efficient intratumoral chemotherapy vol.24, pp.1, 2014, https://doi.org/10.1080/10717544.2017.1309478
  10. Response to transarterial chemoembolization may serve as selection criteria for hepatocellular carcinoma liver transplantation vol.8, pp.53, 2017, https://doi.org/10.18632/oncotarget.20511
  11. High-intensity focused ultrasound combined with transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma : A case report vol.98, pp.31, 2019, https://doi.org/10.1097/md.0000000000016660
  12. Bloodstream Infection and Its Clinical Characteristics and Relevant Factors Associated with Interventional Therapy in a Large Tertiary Hospital: A Six Years Surveillance Study vol.2019, pp.None, 2014, https://doi.org/10.1155/2019/8190475
  13. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma vol.44, pp.10, 2014, https://doi.org/10.1007/s00261-019-02128-7
  14. Hepatic resection versus transarterial chemoembolization in infiltrative hepatocellular carcinoma: A multicenter study vol.35, pp.12, 2020, https://doi.org/10.1111/jgh.15060
  15. Risk factors of infection after transarterial chemoembolization for hepatocellular carcinoma : A protocol for systematic review and meta-analysis vol.100, pp.20, 2014, https://doi.org/10.1097/md.0000000000025851
  16. Infiltrative Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Versus Hepatic Arterial Infusion Chemotherapy vol.11, pp.None, 2014, https://doi.org/10.3389/fonc.2021.747496